Tivantinib ARQ-197 is a small molecule inhibitor of the receptor tyrosine kinase c-Met. It is a promising drug candidate for cancer therapy, particularly in the treatment of hepatocellular carcinoma (HCC). Tivantinib ARQ-197 was first discovered by ArQule Inc. and Daiichi Sankyo Co., Ltd. and has since undergone several clinical trials.
Chemical Name
The chemical name of Tivantinib ARQ-197 is N-(2-{[(3R,5S)-3,5-dimethylpiperidin-1-yl]methyl}-6-(4-(morpholinomethyl)phenyl)imidazo[1,2-b][1,2,4]triazin-2-amine.
Molecular Formula
The molecular formula of Tivantinib ARQ-197 is C23H31N7O.
Formula Weight
The formula weight of Tivantinib ARQ-197 is 421.54 g/mol.
CAS No.
The CAS number of Tivantinib ARQ-197 is 905854-02-6.
Top Ten Keywords from Google and Synonyms
Synonyms: ARQ 197, ARQ-197, ARQ197, TC-2710, N-(2-((3R,5S)-3,5-Dimethylpiperidin-1-yl)methyl)-6-(4-(morpholinomethyl)phenyl)imidazo[1,2-b][1,2,4]triazin-2-amine
Health Benefits of Tivantinib ARQ-197
Tivantinib ARQ-197 has shown promising results in treating various types of cancers, including HCC, non-small cell lung cancer, and colorectal cancer. By inhibiting c-Met, a receptor tyrosine kinase that plays a key role in regulating cell growth and survival, Tivantinib ARQ-197 works to slow or stop the growth of cancer cells.
Potential Effects
Clinical studies have shown that Tivantinib ARQ-197 can effectively treat HCC, which is the most common form of liver cancer. In one phase III trial, researchers found that Tivantinib ARQ-197 improved progression-free survival and overall survival in patients with advanced HCC, when used in combination with another chemotherapy drug.
Product Mechanism
Tivantinib ARQ-197 works by specifically targeting c-Met, a receptor tyrosine kinase that is often overexpressed in cancer cells, leading to increased cell growth and spread. By blocking c-Met, Tivantinib ARQ-197 inhibits the signaling pathways that are critical for cancer cell growth and survival, thereby slowing down or stopping cancer progression.
Safety
Tivantinib ARQ-197 has generally been well-tolerated in clinical trials. However, like all medications, it can cause side effects. Common side effects include fatigue, nausea, vomiting, diarrhea, and decreased appetite. More severe side effects may occur in some patients, such as high blood pressure, bleeding, or liver damage. Patients should be closely monitored for any adverse reactions while taking Tivantinib ARQ-197.
Side Effects
The most common side effects of Tivantinib ARQ-197 include:
More severe side effects may occur in some patients, such as:
Dosing Information
The dosing of Tivantinib ARQ-197 depends on the type of cancer being treated and other individual factors. It is typically administered orally in capsule form, either alone or in combination with other chemotherapy drugs. The recommended dose varies depending on the clinical trial or physician's discretion.
Conclusion
In conclusion, Tivantinib ARQ-197 is a promising drug candidate for cancer therapy, particularly in the treatment of HCC. As a specific inhibitor of c-Met, it shows potential in slowing or stopping cancer progression in tumors that overexpress this receptor tyrosine kinase. While further clinical trials are needed to determine its efficacy and safety, Tivantinib ARQ-197 represents an important step towards precision medicine and molecular targeted therapy in cancer treatment
